Medical Device and Diagnostic Industry May 28, 2014 Jamie Hartford No. 7: RiverVest Venture Partners Passion or the desire to make a difference alone cannot bring about radical changes in the world of medtech. Money and the right guidance are equally crucial. That’s where venture capitalist firms—especially RiverVest Venture Partners—come in. Read More
RiverVest News
RiverVest Venture Partners’ portfolio company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II
ST. LOUIS and SAN DIEGO (May 12, 2014) – RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.
RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner
ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner.
“The Frank Drebin Approach to Healthcare”
“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014. Read more
RiverVest is investor in ZS Pharma’s $55 million financing
St. Louis Business Journal March 7, 2014 Brian Feldt, Reporter Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round. ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday.
RiverVest Venture Partners’ Bradley T. Keller Presents New Treatment for Cholestatic Liver Diseases at The Liver Meeting
ST. LOUIS and WASHINGTON, D.C. (Nov. 5, 2013) –RiverVest Venture Partners’ Bradley T. Keller presents research today on a potential new treatment for cholestatic liver diseases at The Liver Meeting in Washington, D.C.
RiverVest sells portfolio company to Abbott Labs for $310 million
July 15, 2013 ST. LOUIS (St. Louis Business Journal) — Abbott Laboratories is acquiring IDEV Technologies, a RiverVest Venture Partners medical device portfolio company, for $310 million… Read more.
RiverVest Venture Partners’ Medical Device Portfolio Company Sold to Abbott Laboratories for $310 million
ST. LOUIS, MO (July 15, 2013) – RiverVest Venture Partners announced today that Abbott Laboratories is acquiring RiverVest medical device portfolio company IDEV Technologies for $310 million.
Podcast: What Works When It Comes Time To Pitch
Cleveland, OH (July 9, 2013) – In 2012, 108 Northeast Ohio companies raised $212 million in equity capital from angel and venture capitalists to grow their businesses. Still, the process of raising capital is a struggle for many, if not most, entrepreneurs. Imagine convincing potential investors—especially ones you don’t know—to put money into your company […]
RiverVest Venture Partners Names Pharmaceutical Veteran Bradley Keller as Entrepreneur-in-Residence
ST. LOUIS (May 13, 2013) – RiverVest Venture Partners announced today that Bradley Keller, Ph.D. has joined the life sciences venture capital firm as an Entrepreneur-in-Residence.
RiverVest Venture Partners’ O’Donnell Named to Experts Advisory Panel at Stevenage Bioscience Catalyst
ST. LOUIS (March 26, 2013) – RiverVest Venture Partners’ Principal Niall O’Donnell, Ph.D., has been invited to serve on the Experts Panel at Stevenage Bioscience Catalyst, the U.K.’s first open innovation bioscience campus focused on driving early-stage biotech, pharma and medtech developments.
Rady Venture Fund Develops Next Generation Tech Investors
SAN DIEGO, March 20, 2013 /PRNewswire-USNewswire/ — The Rady School of Management’s student-run venture capital fund, the Rady Venture Fund, has participated in a $16 million Series B raise in startup Savara Pharmaceuticals, which is developing an inhalable antibiotic to treat cystic fibrosis patients with lung infections.